Hiroshima-based Phoenix Bio Establishes NYC Office
This article was originally published in PharmAsia News
Hiroshima-based bioventure Phoenix Bio provides proprietary PXB-mice, chimeric mice with humanized livers, for new drug research and development. In recent years, the company has seen increasing orders for the mice from drug makers in the U.S. and Europe. Phoenix Bio estimates sales will triple from 2008 to ¥2 billion by 2010. Aiming to establish a manufacturing and testing presence in the U.S., the company is opening a New York City office, which will be staffed with four to five employees and start operation in July. (Click here for more - Japanese language
You may also be interested in...
Firm supplying all-in-one multivitamin blends rather than packs of multiple pills has four-member advisory board including digital marketing and consumer product marketing specialists and a health care strategist.
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.